Keywords: Tumors (Pre-Treatment), Tumor, IDH1 mutation, glioma, MEGA-PRESS, 2-Hydroxyglutarate, glutamate, GABA, glutathione
Motivation: Detecting isocitrate dehydrogenase 1 (IDH1) mutations via in vivo MRI can significantly aids glioma diagnosis and treatment strategies.
Goal(s): To investigates the use of MEGA-PRESS sequences to non-invasively charaterize the metabolic profile of IDH1 mutation glioma.
Approach: We measured 2-hydroxyglutarate (2HG), glutamate+glutamine (GLX), GABA and glutathione (GSH) inside the glioma from an IDH1(R132H)-mutant and an IDH1-wildtype murine models.
Results: The results unveil distinctive metabolic changes in IDH1 mutation tumors, including elevated 2HG, GLX/GABA ratio, and reduced GSH. These findings offer potential biomarkers for precise diagnosis and therapeutic strategies, highlighting the significant role of MEGA-PRESS in the studies of glioma.
Impact: The study identifies 1H MRS-based biomarkers for non-invasive detection of IDH1 mutation tumors using the MEGA-PRESS sequence. It provides insights into metabolic changes and neurochemical imbalances, aiding early diagnosis, treatment guidance, and monitoring, thus advancing precision oncology.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords